Evercore ISI Sticks to Their Buy Rating for ProQR (PRQR)
In a report released yesterday, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on ProQR, with a price target of $5.00. The company’s shares closed yesterday at $1.89.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Clark-Gartner covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Rocket Pharmaceuticals, and Krystal Biotech. According to TipRanks, Clark-Gartner has an average return of 8.5% and a 52.56% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ProQR with a $7.86 average price target, a 315.87% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $12.00 price target.
Based on ProQR’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $4.52 million and a GAAP net loss of $10.08 million. In comparison, last year the company earned a revenue of $4.48 million and had a GAAP net loss of $7.7 million
